A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986435/MYK-224 in Participants with Heart Failure with Heart Failure with Preserved Ejection Fraction (HFpEF) (CV029-1001 (AURORA))

Principal Investigator

Dr Andrew Lewis

Contact us

Email: cvm_nurses@cardiov.ox.ac.uk

IRAS number

1011859